Moreover, the administration of “secondary” adjuvant trastuzumab in patients with HER2(−) breast cancer can eliminate chemotherapy-resistant CK19 mRNA-positive CTCs [30], in contrast to the Treat CTC phase II trial that failed to prove the efficacy of trastuzumab in the detection rate of CTC [31]. The gene discussed is ERBB2; the disease is breast cancer.